FDA Approval: Repotrectinib, a ROS1 and NTRK Inhibitor
Podcast | English | 37 Min
Image For Activity Cover
Cost
$0.00
Credit
No Credit Offered
Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.
Podcast Hosts:
  • Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, USA 

Podcast Guests: 

  • Benjamin Besse, MD, PhD, Director of Clinical Research, Gustave Roussy, France
  • Jessica Lin, MD, Assistant Professor of Medicine, Harvard School of Medicine, Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital, USA
Powered By